Image

Building on our recent announcement of a new office in the GCC, today CureLab announces its expansion into the European Union

November 10, 2020
CureLab_EU

CureLab Oncology Establishes Operations in Europe

CureLab is expanding its global presence with a new office from which it will base operations in the European Union; Ricarda Cramer joins as business development director
October 21, 2020

CureLab Oncology Establishes Operations in the Gulf Region

CureLab is expanding its global presence with a new office in the Gulf Cooperation Council (GCC) region; CureLab's partners in the region will test the efficacy of the company's DNA-based products against cancers and non-cancerous diseases of chronic inflammation
October 14, 2020

CureLab Oncology Appoints The Honorable David J. Shulkin, M.D. to its Scientific Advisory Board

Former US Secretary of Veterans Affairs and internationally known healthcare industry leader to advise on partnerships for upcoming clinical trials and market entry strategy for CureLab’s Elenagen cancer therapy
October 5, 2020

CureLab Oncology Receives Pre-IND Response from FDA Regarding Planned Trial for Triple Negative Breast Cancer

Feedback from FDA was constructive and includes recommendations to test cumulative toxicity and clinical benefits progression; this has led the company to consider a shorter trial design for Phase II.